10-94981296-A-C
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 2P and 12B. PM5BP4_StrongBA1
The ENST00000260682.8(CYP2C9):c.1075A>C(p.Ile359Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0634 in 1,613,890 control chromosomes in the GnomAD database, including 3,705 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response,other (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I359T) has been classified as Likely benign.
Frequency
Consequence
ENST00000260682.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP2C9 | NM_000771.4 | c.1075A>C | p.Ile359Leu | missense_variant | 7/9 | ENST00000260682.8 | NP_000762.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP2C9 | ENST00000260682.8 | c.1075A>C | p.Ile359Leu | missense_variant | 7/9 | 1 | NM_000771.4 | ENSP00000260682 | P1 | |
CYP2C9 | ENST00000643112.1 | c.*84A>C | 3_prime_UTR_variant, NMD_transcript_variant | 6/8 | ENSP00000496202 |
Frequencies
GnomAD3 genomes AF: 0.0495 AC: 7523AN: 152122Hom.: 245 Cov.: 32
GnomAD3 exomes AF: 0.0631 AC: 15849AN: 251154Hom.: 662 AF XY: 0.0682 AC XY: 9258AN XY: 135700
GnomAD4 exome AF: 0.0649 AC: 94818AN: 1461650Hom.: 3461 Cov.: 32 AF XY: 0.0662 AC XY: 48127AN XY: 727130
GnomAD4 genome AF: 0.0494 AC: 7516AN: 152240Hom.: 244 Cov.: 32 AF XY: 0.0499 AC XY: 3715AN XY: 74432
ClinVar
Submissions by phenotype
Warfarin response Other:3
drug response, no assertion criteria provided | research | Faculty of Pharmacy, Damascus University | - | rs1057910 is a SNP in the CYP2C9 gene and is linked to poor warfarin metabolism and risk of GI bleeding with warfarin, rs1057910 is associated with reduced enzyme activity and lower clearance rates of warfarin leading to higher rates of warfarin concentration likely responsive |
drug response, no assertion criteria provided | literature only | OMIM | Jun 15, 2012 | - - |
drug response, no assertion criteria provided | research | Pharmacogenomics Lab, Chungbuk National University | Aug 31, 2010 | - likely responsive |
Phenytoin response Other:2
drug response, no assertion criteria provided | case-control | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Sep 24, 2020 | May cause toxicity/ADR and poor metabolism/PK No CYP2C9 function |
drug response, no assertion criteria provided | literature only | OMIM | Jun 15, 2012 | - - |
Piroxicam response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals. Poor metabolizer |
Glipizide response Other:1
drug response, no assertion criteria provided | literature only | OMIM | Jun 15, 2012 | - - |
Lesinurad response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects. Poor metabolizer |
not provided Other:1
other, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 10, 2015 | - Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles). |
Tolbutamide response Other:1
drug response, no assertion criteria provided | literature only | OMIM | Dec 30, 2010 | - - |
Flurbiprofen response Other:1
drug response, criteria provided, single submitter | curation | Medical Genetics Summaries | Feb 11, 2019 | The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance. Poor metabolizer |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at